OncoMatch/Clinical Trials/NCT06566807
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
Is NCT06566807 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Orelabrutinib, obinutuzumab for marginal zone lymphoma.
Treatment: Orelabrutinib, obinutuzumab — This is a multi-center, prospective study. The main purpose is to evaluate the efficacy and safety of Orelabrutinib combined with Obinutuzumab for previously untreated MZL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20-positive)
Histopathologically confirmed CD20-positive marginal zone lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
absolute neutrophil count ≥1.5×10^9/l, platelets ≥75×10^9/l, hemoglobin ≥75g/l; if accompanied by bone marrow invasion, absolute neutrophil count ≥1.0×10^9/l, platelets ≥50×10^9/l, hemoglobin ≥50g/l
Kidney function
serum creatinine ≤1.5 uln
Liver function
total bilirubin ≤1.5 uln, ast or alt ≤2 uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify